메뉴 건너뛰기




Volumn 52, Issue 1, 2013, Pages 347-353

Anti-tumor necrosis factor treatment in cherubism - Clinical, radiological and histological findings in two children

Author keywords

Adalimumab; Cherubism; SH3 binding protein 2; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ADENINE; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CYTOSINE; HISTIDINE; LEUCINE; PROLINE; THYMINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 84868566988     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.10.003     Document Type: Article
Times cited : (42)

References (21)
  • 1
    • 0034567805 scopus 로고    scopus 로고
    • Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature
    • Von Wowern N. Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000, 90:765-772.
    • (2000) Oral Surg Oral Med Oral Pathol Oral Radiol Endod , vol.90 , pp. 765-772
    • Von Wowern, N.1
  • 4
    • 67650251439 scopus 로고    scopus 로고
    • Diagnosis and treatment of familial cherubism characterized by early onset and rapid development
    • Mortellaro C., Bello L., Lucchina A.G., Pucci A. Diagnosis and treatment of familial cherubism characterized by early onset and rapid development. J Craniofac Surg 2009, 20:116-120.
    • (2009) J Craniofac Surg , vol.20 , pp. 116-120
    • Mortellaro, C.1    Bello, L.2    Lucchina, A.G.3    Pucci, A.4
  • 7
    • 0034977079 scopus 로고    scopus 로고
    • Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism
    • Ueki Y., Tiziani V., Santanna C., Fukai N., Maulik C., Garfinkle J., et al. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001, 28:125-126.
    • (2001) Nat Genet , vol.28 , pp. 125-126
    • Ueki, Y.1    Tiziani, V.2    Santanna, C.3    Fukai, N.4    Maulik, C.5    Garfinkle, J.6
  • 8
    • 83255171065 scopus 로고    scopus 로고
    • Loss of tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism
    • Levaot N., Voytyuk O., Dimitriou I., Sircoulomb F., Chandrakumar A., Deckert M., et al. Loss of tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 2011, 147:1324-1339.
    • (2011) Cell , vol.147 , pp. 1324-1339
    • Levaot, N.1    Voytyuk, O.2    Dimitriou, I.3    Sircoulomb, F.4    Chandrakumar, A.5    Deckert, M.6
  • 9
    • 83255171058 scopus 로고    scopus 로고
    • Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease
    • Guettler S., LaRose J., Petsalaki E., Gish G., Scotter A., Pawson T., et al. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011, 147:1340-1354.
    • (2011) Cell , vol.147 , pp. 1340-1354
    • Guettler, S.1    LaRose, J.2    Petsalaki, E.3    Gish, G.4    Scotter, A.5    Pawson, T.6
  • 10
    • 12844271053 scopus 로고    scopus 로고
    • The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor
    • Foucault I., Le Bras S., Charvet C., Moon C., Altman A., Deckert M. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood 2005, 105:1106-1113.
    • (2005) Blood , vol.105 , pp. 1106-1113
    • Foucault, I.1    Le Bras, S.2    Charvet, C.3    Moon, C.4    Altman, A.5    Deckert, M.6
  • 11
    • 44149119302 scopus 로고    scopus 로고
    • SH3BP2 is an activator of NFAT activity and osteoclastogenesis
    • Lietman S.A., Yin L., Levine M.A. SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun 2008, 371:644-648.
    • (2008) Biochem Biophys Res Commun , vol.371 , pp. 644-648
    • Lietman, S.A.1    Yin, L.2    Levine, M.A.3
  • 12
    • 33845988776 scopus 로고    scopus 로고
    • Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice
    • Ueki Y., Lin C.Y., Senoo M., Ebihara T., Agata N., Onji M., et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 2007, 128:71-83.
    • (2007) Cell , vol.128 , pp. 71-83
    • Ueki, Y.1    Lin, C.Y.2    Senoo, M.3    Ebihara, T.4    Agata, N.5    Onji, M.6
  • 14
    • 84874445437 scopus 로고    scopus 로고
    • Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
    • Burmester G.R., Panaccione R., Gordon K.B., McIlraith M.J., Lacerda A.P.M. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012, http://dx.doi.org/10.1136/annrheumdis-2011-201244.
    • (2012) Ann Rheum Dis
    • Burmester, G.R.1    Panaccione, R.2    Gordon, K.B.3    McIlraith, M.J.4    Lacerda, A.P.M.5
  • 15
    • 78650990577 scopus 로고    scopus 로고
    • Pediatric rheumatology: JIA, treatment and possible risk of malignancies
    • Ruperto N., Martini A. Pediatric rheumatology: JIA, treatment and possible risk of malignancies. Nat Rev Rheum 2011, 7:6-7.
    • (2011) Nat Rev Rheum , vol.7 , pp. 6-7
    • Ruperto, N.1    Martini, A.2
  • 17
    • 33846018444 scopus 로고    scopus 로고
    • Jawing about TNF: new hope for cherubism
    • Novack D.V., Faccio R. Jawing about TNF: new hope for cherubism. Cell 2007, 128:15-17.
    • (2007) Cell , vol.128 , pp. 15-17
    • Novack, D.V.1    Faccio, R.2
  • 20
    • 79955648483 scopus 로고    scopus 로고
    • Ineffectiveness of tumour necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism
    • Pagnini I., Simonini G., Mortilla M., Giani T., Pascoli L., Cimaz R. Ineffectiveness of tumour necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism. Clin Exp Rheumatol 2011, 29:147.
    • (2011) Clin Exp Rheumatol , vol.29 , pp. 147
    • Pagnini, I.1    Simonini, G.2    Mortilla, M.3    Giani, T.4    Pascoli, L.5    Cimaz, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.